Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline

Monrovia, California-based Xencor Inc.'s latest funding exercise is a public share offering to raise some $110m after expenses to advance its immuno-oncology pipeline.

Pipeline

Xencor Inc.'s plan to publicly issue 4,585,000 shares of its common stock is further evidence the clinical-stage US biopharmaceutical company and its product pipeline are maturing.

The NASDAQ-listed biotech Dec. 1 said it filed a preliminary prospectus with the US Securities and Exchange Commission...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip